Progress and Challenges in Precision Medicine

Dr. Mukesh Verma is a Program Director and Chief in the Methods and Technologies Branch (MTB), Epidemiology and Genetics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Before coming to the DCCPS, he was a Program Director in the Division of Cancer Prevention (DCP), NCI, providing direction in the areas of biomarkers, early detection, risk assessment and prevention of cancer, epigenetics, epidemiology, and cancers associated with infectious agents. Since joining the NCI, he has sought to champion the visibility of and investment in cancer epigenetics research both within the Institute and across other federal and non-governmental agencies, and to raise public awareness about controlling cancer. He represents NIH in Common Fund Programs on Epigenomics, Metabolomics, and Molecular Transducers of Physical Activity. Dr. Mukesh Verma holds a M.Sc. from Pantnagar University and a Ph.D. from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University Medical Center. He has published 161 research articles and reviews and edited five books in cancer biomarkers, epigenetics and epidemiology field. Dr. Debmalya Barh is currently a Visiting Full Professor (Titular, Grade-E) in Bioinformatics and Precision Health at the Department of Genetics, Ecology, and Evolution, ICB, Federal University of Minas Gerais, Brazil and honorary scientist of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. With over 20 years of experience, he has led academic, healthcare, molecular diagnostic, and bioinformatics industry endeavors. He works with more than 400 scientists from 100+ top ranked organizations across 40+ countries and has 220+ publications and a branded editor for 10+ cutting-edge omics related reference books. He is an expert in in precision/personalized health and integrative omics-based biomarker and target discovery in infectious and complex lifestyle diseases.

• 1. Introduction: Every Individual Is Different and Precision Medicine Offers Options for Disease Control and Treatment2. Clinical Next-Generation Sequencing: Enabling Precision Medicine3. Phenotyping in Precision Medicine4. Cancer Genetic Screening and Ethical Considerations for Precision Medicine5. Precision Medicine in Primary Health Care6. Population Approach to Precision Medicine7. Regulation of Genomic Testing in the Era of Precision Medicine8. Image-Based Modeling and Precision Medicine9. Sharing Outside the Sandbox? The Child’s Right to an Open Data Sharing Future in Genomics and Personalized Medicine10. Lessons Learned From Cohort Studies, and Hospital-Based Studies and Their Implications in Precision Medicine11. Clinical Trials in Precision Medicine12. Time to Educate Physicians and Hospital Staff in Electronic Medical Records for Precision Medicine13. Computational Approaches in Precision Medicine14. Handling Big Data in Precision Medicine15. Trends in Precision Medicine16. Personalized Medicine: Interdisciplinary Perspective, World Tidal Wave, and Potential Growth for the Emerging Countries